AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02842762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: Elective cardiac surgery, with use of cardiopulmonary bypass.
Study NCT02842762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 3D TEE
Description: Intraoperatively, all patients will be monitored by means of TEE
Study NCT02842762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D TEE
Description: Intraoperatively, all patients will be monitored by means of TEE
Study NCT02842762 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pacemaker lead
Description: All patients will have a epicardial pacemaker lead in situ.
Study NCT02842762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker lead
Description: All patients will have a epicardial pacemaker lead in situ.
Study NCT02030002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APC Flash-Free Adhesive Coated Appliance System
Description: APC Flash-Free Adhesive Coated Appliance System
Study NCT02030002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APC II Adhesive Coated Appliance System
Description: APC II Adhesive Coated Appliance System
Study NCT00774930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: deep s.c. injection, 120 mg, every 4 weeks (±3 days).
Study NCT00774930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
Study NCT03385343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VLE imaging for staging EAC
Description: Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
Study NCT01097707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY500307
Description: Administered orally, daily for 24 weeks
Study NCT01097707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, daily for 24 weeks
Study NCT01652495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
Study NCT01652495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
Study NCT00480935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (Sutent)
Description: Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
Study NCT04948281 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03093103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
Study NCT03093103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
Study NCT01843153 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Study NCT04367259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis
Description: Temporomandibular joint arthrocentesis
Study NCT01986270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01986270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Description: 40mg oral
Study NCT01986270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Description: 80mg oral
Study NCT01986270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Description: 25mg oral
Study NCT01986270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Description: 50mg oral
Study NCT00870077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProWHEY 94 CFM, SponserR
Description: 3 times 20g per day
Study NCT00939822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg Simvastatin/day
Study NCT00939822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT01072630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
Study NCT03167242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine Solid Dispersion Formulation
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
Study NCT01072630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo, also in tablet form taken orally, once daily in the morning.
Study NCT01846377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G4H-Diab-Nano
Description: The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
Study NCT00810433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GO-LIF - Guided Oblique Lumbar Interbody Fusion
Description: All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused.
Study NCT02005770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study NCT02005770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT04138108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
Study NCT00089921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: 60 mg capsule three times daily for 12 weeks
Study NCT00089921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: 30 mg capsule three times daily for 12 weeks
Study NCT00089921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules three times daily and one tablet daily
Study NCT00089921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: 100 mg tablet once daily for 12 weeks
Study NCT04694261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SM-ART
Description: Intervention is a group based training delivered by midwives on SM-ART module. These training will consist of 6 sessions, one per week for 90 to 120 minutes each.
Study NCT03943472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
Study NCT03943472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT03943472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study NCT03943472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune inhibitors
Description: Immune inhibitors
Study NCT00020735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Study NCT00020735 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Study NCT00020735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00920075 — intervention group
Intervention type: DRUG
Intervention: Alendronate (Fosamax)
Description: Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
Study NCT04329468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS-MCE
Description: The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8962
Description: MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recFSH
Description: Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recFSH
Description: Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: 0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: 0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human Chorionic Gonadotropin (hCG)
Description: Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human Chorionic Gonadotropin (hCG)
Description: Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
Study NCT01599494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
Study NCT01129700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: short-course preoperative chemoradiotherapy
Description: Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day).
Study NCT01411852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium Chloride 250 mL bolus
Description: Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
Study NCT01411852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride 2000 mL bolus
Description: Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
Study NCT03786380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin 10 μg
Description: Relamorelin 10 μg injected subcutaneously twice daily.
Study NCT05643391 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization using Holmium-166
Description: This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
Study NCT00572845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weaning of Antispasticity Medication
Description: Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
Study NCT01328938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCPGC 3.6mg
Description: Stage I:Single blinded
Study NCT01328938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCPGC 6mg
Description: Stage I: Single blinded;
Study NCT04514510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days.
Study NCT04514510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days.
Study NCT04571788 — intervention group
Intervention type: PROCEDURE
Intervention: Foldable Capsular Buckle
Description: Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera >10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.
Study NCT04571788 — intervention group
Intervention type: PROCEDURE
Intervention: Silicone scleral padding
Description: Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
Study NCT00990795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
Study NCT00990795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
Study NCT02503852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puregraft System
Description: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Study NCT02503852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puregraft System
Description: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Study NCT01328938 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (pegfilgrastim) 6mg
Description: Stage II: Active comparator, double blinded